Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin’s lymphoma (fNHL) whose disease has resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenhalgh, Janette, Bagust, Adrian, Boland, Angela, Blundell, Michaela, Oyee, James, Beale, Sophie, Dundar, Yenal, Hockenhull, Juliet, Proudlove, Chris, Chu, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing AG 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654180/
https://www.ncbi.nlm.nih.gov/pubmed/23576017
http://dx.doi.org/10.1007/s40273-013-0043-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654180/
https://www.ncbi.nlm.nih.gov/pubmed/23576017
http://dx.doi.org/10.1007/s40273-013-0043-8

Ejemplares similares